Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Anika Therapeutics (ANIK) over the last 15 years, with Q3 2025 value amounting to $13000.0.

  • Anika Therapeutics' Gains from Investment Securities fell 9941.53% to $13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year increase of 11855.24%. This contributed to the annual value of $2.1 million for FY2024, which is 1524.28% up from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Gains from Investment Securities is $13000.0, which was down 9941.53% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Gains from Investment Securities ranged from a high of $2.3 million in Q1 2024 and a low of -$13.6 million during Q2 2021
  • In the last 5 years, Anika Therapeutics' Gains from Investment Securities had a median value of $1.5 million in 2022 and averaged -$220562.9.
  • The largest annual percentage gain for Anika Therapeutics' Gains from Investment Securities in the last 5 years was 11755.19% (2022), contrasted with its biggest fall of 139151.52% (2022).
  • Quarter analysis of 5 years shows Anika Therapeutics' Gains from Investment Securities stood at $825000.0 in 2021, then plummeted by 1391.52% to -$10.7 million in 2022, then skyrocketed by 110.14% to $1.1 million in 2023, then skyrocketed by 36.11% to $1.5 million in 2024, then plummeted by 99.12% to $13000.0 in 2025.
  • Its last three reported values are $13000.0 in Q3 2025, $1.8 million for Q2 2025, and $1.9 million during Q1 2025.